Division of Musculoskeletal Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Division of Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit Street - YAW 6, Boston, MA, 02114, USA.
Skeletal Radiol. 2022 Jan;51(1):31-41. doi: 10.1007/s00256-021-03771-2. Epub 2021 Apr 4.
F-Fluorodeoxyglucose (FDG) PET has been used for staging of hematologic malignancies for years. In multiple myeloma, this imaging modality can be used in many different scenarios, including initial staging, evaluation of treatment response, and investigation of residual disease or early relapse. FDG PET-CT has excellent diagnostic performance, similar to other advanced imaging modalities such as whole-body CT and MRI, and it is particularly helpful for the assessment of extramedullary disease. It also offers important prognostic information on survival and risk of relapse, both at baseline and after therapy. This review will cover the main applications, advantages, and limitations of FDG PET-CT in multiple myeloma and related clonal plasma cell proliferative disorders, such as smoldering multiple myeloma and plasmacytoma.
氟代脱氧葡萄糖（FDG）正电子发射断层扫描（PET）已用于血液恶性肿瘤多年。在多发性骨髓瘤中，这种成像方式可用于多种不同的情况，包括初始分期、治疗反应评估以及残留疾病或早期复发的研究。FDG-PET-CT 具有出色的诊断性能，与全身 CT 和 MRI 等其他先进的成像方式相似，特别有助于评估骨髓外疾病。它还提供了关于生存和复发风险的重要预后信息，包括在基线和治疗后。这篇综述将涵盖 FDG-PET-CT 在多发性骨髓瘤和相关克隆浆细胞增生性疾病（如冒烟型多发性骨髓瘤和浆细胞瘤）中的主要应用、优势和局限性。
